Breathing new life into proven medicines
Optinose (optinose.com) scores 72 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 30th percentile of 17208 Healthcare brands.
Optinose is a specialty pharmaceutical company headquartered in Yardley, United States, founded in 2000. It develops and markets innovative treatments for patients with diseases managed by ear, nose, and throat (ENT) and allergy specialists. The company's proprietary Bi-Directional Exhalation Delivery System is designed to improve how medication is delivered to the nasal passages, aiming to make established drugs more effective for underserved ENT and allergy conditions.
| Brand Name | Optinose |
|---|---|
| Domain | optinose.com |
| Industry | Healthcare |
| Founded | 2000 |
| Headquarters | Yardley |
| Main Competitors | GSK (83/100), Sanofi (90/100), AstraZeneca (82/100), Teva Pharmaceuticals (86/100), Bausch Health (81/100), Impel Pharmaceuticals (74/100) |
Moz Domain Authority 39/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Optinose is a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat (ENT) and …" (Meta description: 29 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, HubSpot.
Social footprint: verified profiles on LinkedIn, Facebook, Instagram, YouTube; no detected presence on X (Twitter), GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Optinose?", Claude could identify the brand as of October 2026. Optinose is a pharmaceutical company that developed the Exhalation Delivery System, a proprietary nasal spray device technology designed to deliver drugs deeper into the nasal cavity than conventional nasal sprays. Its lead product is Xhance, a fluticasone propionate nasal spray Best known for Its Exhalation Delivery System (EDS) nasal spray technology and its product Xhance for chronic sinusitis and nasal polyps.
When asked "Best brands similar to Optinose?", Claude would recommend Optinose as of October 2026. It would come up naturally in discussions of ENT or nasal drug delivery pharmaceutical companies due to its distinctive delivery technology and approved product.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Optinose's main competitors in Healthcare: GSK (83/100), Sanofi (90/100), AstraZeneca (82/100), Teva Pharmaceuticals (86/100), Bausch Health (81/100).
Sources: Brand Analyzer scan
Optinose is a specialty pharmaceutical company headquartered in Yardley, United States, founded in 2000. It focuses on creating and marketing innovative products for patients with diseases treated by ear, nose, and throat (ENT) and allergy specialists.
Sources: Optinose official site
Optinose has limited AI-search visibility, scoring 28/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 22, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Optinose official site
Optinose was founded in 2000. Optinose operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Optinose is headquartered in Yardley. Optinose operates in the Healthcare category.
Sources: Wikidata
Optinose develops and commercializes pharmaceutical products aimed at treating ENT and allergy-related conditions. It uses its proprietary Bi-Directional Exhalation Delivery System to improve how medication is delivered to the nasal passages, aiming to transform established drugs into more effective treatments for underserved conditions.
Sources: Optinose official site
Optinose scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Optinose official site
Optinose offers specialty pharmaceutical products for ENT and allergy conditions, delivered using its proprietary Bi-Directional Exhalation Delivery System. This technology is designed to enhance how medication reaches the nasal passages, transforming established drugs into more effective treatments for patients with these conditions.
Sources: Optinose official site
Optinose can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Optinose official site
Optinose's products are used by patients with ENT and allergy-related conditions, and are prescribed by ear, nose, and throat specialists and allergy specialists who treat these patients.
Sources: Optinose official site
Optinose is known for its proprietary Bi-Directional Exhalation Delivery System, a novel drug delivery technology designed to improve the effectiveness of medications for ENT and allergy conditions by ensuring the drug reaches the targeted nasal areas more effectively than conventional delivery methods.
Sources: Optinose official site
Optinose scores 28/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Optinose has a weak AI-visibility profile at 28/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 39/100 and thin schema.org structured data. In a live check, Claude could already identify Optinose from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Optinose: OOAQ (72/100), Onmedu.edu (72/100), Options Community Services (72/100), Orchid Orthopedic Solutions (72/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.